Roflumilast is a selective PDE4 inhibitor that is approved by the FDA for the treatment of severe chronic obstructive pulmonary disease (COPD) (Janjua et al. 2020). The gene discussed is PDE4A; the disease is chronic obstructive pulmonary disease.